Viridian Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
VRDN Nasdaq 8731 https://www.viridiantherapeutics.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Viridian Therapeutics Inc

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jun 5th, 2023 8:05 pm
Viridian Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update - May 9th, 2023 8:01 pm
Viridian Therapeutics Announces Partnership with Drug Delivery Innovator Enable Injections - May 8th, 2023 12:00 pm
Viridian Therapeutics to Webcast First Quarter 2023 Financial Results and Corporate Update on May 9, 2023 - May 2nd, 2023 12:00 pm
UPDATE – Viridian Therapeutics Announces Presentations at the 2023 Annual Meeting of the Association for Research in Vision and Ophthalmology - Apr 20th, 2023 5:41 pm
Viridian Therapeutics Announces Presentations at the 2023 Annual Meeting of the Association for Research in Vision and Ophthalmology - Apr 20th, 2023 12:00 pm
TipRanks ‘Perfect 10’ List: 2 Top-Rated Stocks Potentially Undervalued by ~90% - Apr 16th, 2023 1:50 pm
Viridian Therapeutics Appoints Tony Casciano as Chief Commercial Officer - Apr 12th, 2023 12:00 pm
Viridian Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Updates - Mar 8th, 2023 12:00 pm
Viridian Therapeutics Announces Presentations at the 49th Annual Meeting of the North American Neuro-Ophthalmology Society - Mar 7th, 2023 1:00 pm
Viridian Therapeutics to Webcast Fourth Quarter and Full Year 2022 Financial Results on March 8, 2023 - Mar 1st, 2023 1:00 pm
Viridian Therapeutics to Participate in Cowen’s 43rd Annual Health Care Conference - Feb 28th, 2023 1:00 pm
Viridian Therapeutics to Participate in the SVB Securities Virtual Global Biopharma Conference - Feb 7th, 2023 1:00 pm
Viridian Appoints Scott Myers as President and Chief Executive Officer - Feb 6th, 2023 12:00 pm
Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating Low Dose VRDN-001 in Patients with Thyroid Eye Disease (TED) - Jan 8th, 2023 1:00 pm
Viridian Therapeutics to Webcast Presentation at the 41st Annual J.P. Morgan Healthcare Conference - Jan 3rd, 2023 1:00 pm
Viridian Therapeutics Announces First Patient Enrolled in the ‘THRIVE’ Phase 3 Trial in Patients With Thyroid Eye Disease - Dec 21st, 2022 12:00 pm
Viridian Therapeutics To Participate In The Evercore ISI HealthCONx Conference - Nov 28th, 2022 12:00 pm
Viridian Therapeutics Third Quarter 2022 Earnings: Beats Expectations - Nov 16th, 2022 10:10 am
Viridian Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Updates - Nov 14th, 2022 12:01 pm